Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical
company developing targeted RNAi therapeutics, today announced that it
will present data on the Dynamic Polyconjugate (DPC) siRNA delivery
technology at two upcoming scientific conferences.
Scheduled conference presentations include the following:
EuroTIDES 2013 – Prague, Czech Republic, November 13-14
November 14, 2013 – An oral presentation titled, “DPC
technology for delivery of therapeutic siRNAs,” will be presented by
David Lewis, Ph.D., Chief Scientific Officer;
Oligonucleotide & Peptide Based Therapeutics Congress – San
Diego, CA, USA, November 18-19
November 19, 2013 – An oral presentation titled, “Targeted
delivery of therapeutic siRNAs using DPC technology,” will be
presented by David Lewis, Ph.D., Chief Scientific Officer.
About Arrowhead Research Corporation
Arrowhead Research Corporation is a biopharmaceutical company developing
targeted RNAi therapeutics. The company is leveraging its proprietary
drug delivery technologies to develop targeted drugs based on the RNA
interference mechanism that efficiently silence disease-causing genes.
Arrowhead technologies also enable partners to create peptide-drug
conjugates that specifically home to cell types of interest while
sparing off-target tissues. Arrowhead’s pipeline includes clinical
programs in chronic hepatitis B virus and obesity and partner-based
programs in oncology.
For more information please visit http://www.arrowheadresearch.com,
or follow us on Twitter @ArrowRes.
To be added to the Company’s email list to receive news directly, please
send an email to firstname.lastname@example.org
Copyright Business Wire 2013